Description
Product Description: IGF1 LR3 Magnus Pharma
Are you looking to take your bodybuilding journey to the next level? Look no further than IGF1 LR3 by Magnus Pharma. This powerful growth factor supplement is designed to enhance muscle growth, improve recovery, and boost overall performance. With its unique formulation and potent benefits, IGF1 LR3 is a must-have for both beginners and experienced bodybuilders.
Specific Details and Features
- Brand: Magnus Pharma
- Product: IGF1 LR3
- Form: Injectable solution
- Quantity: 1 vial (1mg)
- Active Ingredient: Insulin-like Growth Factor 1 Long R3
Benefits
- Stimulates muscle growth and hypertrophy
- Enhances protein synthesis for faster recovery
- Increases strength and endurance
- Improves overall athletic performance
- Boosts fat burning and promotes lean muscle mass
Potential Side Effects
While IGF1 LR3 is generally well-tolerated, it’s important to be aware of potential side effects, which may include:
- Hypoglycemia (low blood sugar)
- Joint pain
- Headaches
- Water retention
- Increased risk of hypoglycemia in individuals with diabetes
Uses and Dosage
IGF1 LR3 is commonly used for:
- Promoting muscle growth and recovery
- Increasing strength and endurance
- Improving athletic performance
For beginners, a recommended dosage is 20-40mcg per day, divided into two doses. Experienced bodybuilders may increase the dosage to 60-80mcg per day, also divided into two doses. It is important to consult with a healthcare professional or fitness expert before starting any new supplement regimen.
Value and Why Buy from uk-steroids-shop.com
When you purchase IGF1 LR3 from uk-steroids-shop.com, you can expect:
- Authentic Magnus Pharma product
- High-quality and pure formulation
- Discreet packaging and fast shipping
- Competitive prices and special offers
- Excellent customer service and support
With our UK-based website, you can trust that you are buying from a reliable source that prioritizes customer satisfaction and delivers genuine products.
Reviews
There are no reviews yet.